Antifungal therapy, especially with the azoles, could promote the incidence of less
susceptible isolates of Cryptococcus neoformans and C. gattii species complexes (SC) …

When method-dependent categorical endpoints are available, namely either BPs or ECVs,
MICs could aid in selecting the best treatment agent (s). BPs can categorize an isolate as …

Introduction The Cryptococcus neoformans/gattii species complexes are a leading cause of
fatality among HIV-infected patients. Despite the unavailability of clinical breakpoints (CBPs) …

Cryptococcus neoformans and C. gattii are the etiologic agents of cryptococcosis, a life-
threatening disease in both immunocompromised and immunocompetent hosts. Antifungal …

With the widespread use of long-term fluconazole prophylaxis and suppressive treatment,
the potential development of fluconazole resistance poses a threat to the management of …

Objectives: In cryptococcosis, fluconazole is a standard prophylactic, therapeutic and
maintenance option, particularly in the expanding HIV/AIDS group. However, its excessive …

Fluconazole is the most commonly used antifungal agent for both the treatment of
cryptococcal meningitis, and for prophylaxis against the disease. However, its prolonged …

This study presents antifungal susceptibility data for environmental isolates of Cryptococcus
neoformans serotype A (n= 32) and Cryptococcus gattii serotype B (n= 18) to fluconazole …

Abstract Purpose of Review We reviewed data on amphotericin B (AmB) tolerance among
Cryptococcus neoformans/C. gattii species complex clinical isolates and present our results …

Heteroresistance, defined as the occurrence of apparently homogeneous subpopulations of
microbial cells showing different levels of antimicrobial susceptibility is a problem that has …